{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:17:02Z","timestamp":1783437422739,"version":"3.54.6"},"reference-count":20,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019637","name":"Amgen K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid eye disease (TED) causes functional and psychosocial morbidity, but little is known about the patient-experienced burden in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess health-related quality of life (QOL) and psychological well-being among TED patients using standardized quantitative instruments and discuss patient-reported outcomes of patients in Japan compared to the United States, Europe, and Asia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is the first Japanese nationwide cross-sectional survey that shows a natural history of QOL prior to the launch of teprotumumab outside of the United States. Fifty-six TED patients were recruited and answered questionnaires including the Short-Form 12-Item Survey version 2 scores (SF-12v2), Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL), Hospital Anxiety Depression Scale, and Client Satisfaction Questionnaire 8. Disease activity and severity were classified based on European Group on Graves' Orbitopathy criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>While the SF-12v2 physical component summary and mental component summary scores were similar to population norms, SF-12v2 role component summary scores (mean = 39.5) were notably below the national normal. GO-QOL appearance-related\/psychosocial scores were impaired as well as SF-12v2 and were particularly lower in active disease (52.5 vs 73.3; P = .004). The presence of symptoms such as pain with eye movement, eyelid swelling, strabismus, upper eyelid retraction, and proptosis was significantly associated with lower role\/social functioning and satisfaction with care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TED imposes a significant psychosocial burden, particularly in active disease and among those with symptoms involving structure changes. Psychosocial support and targeted symptom control may improve patient-centered outcomes in TED.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvag069","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:43:05Z","timestamp":1774442585000},"source":"Crossref","is-referenced-by-count":0,"title":["Quality of life and psychosocial well-being in thyroid eye disease in Japan: pre-teprotumumab national survey"],"prefix":"10.1210","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1050-4594","authenticated-orcid":false,"given":"Shun","family":"Emoto","sequence":"first","affiliation":[{"name":"NPO ASrid , Tokyo 113-0033 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1667-2674","authenticated-orcid":false,"given":"Yoshito","family":"Bushita","sequence":"additional","affiliation":[{"name":"Value, Access & Policy, Amgen K.K., Tokyo 107-6239 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Nagase","sequence":"additional","affiliation":[{"name":"Value, Access & Policy, Amgen K.K., Tokyo 107-6239 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-4255","authenticated-orcid":false,"given":"Kunihiro","family":"Nishimura","sequence":"additional","affiliation":[{"name":"NPO ASrid , Tokyo 113-0033 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0415-5005","authenticated-orcid":false,"given":"Yuji","family":"Hiromatsu","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Shin Koga Hospital , Fukuoka 830-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9565-5404","authenticated-orcid":false,"given":"Yukiko","family":"Nishimura","sequence":"additional","affiliation":[{"name":"NPO ASrid , Tokyo 113-0033 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"5","key":"2026070710463327400_bvag069-B1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2169\/internalmedicine.53.1518","article-title":"Graves\u2019 ophthalmopathy: epidemiology and natural history","volume":"53","author":"Hiromatsu","year":"2014","journal-title":"Intern Med"},{"issue":"16","key":"2026070710463327400_bvag069-B2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2026070710463327400_bvag069-B3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"2026070710463327400_bvag069-B4","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40123-021-00385-8","article-title":"Quality of life in patients with chronic thyroid eye disease in the United States","volume":"10","author":"Cockerham","year":"2021","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"2026070710463327400_bvag069-B5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ajo.2011.02.018","article-title":"Quality of life in a German Graves\u2019 orbitopathy population","volume":"152","author":"Ponto","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"2026070710463327400_bvag069-B6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/bjo.88.1.75","article-title":"Assessing quality of life in Australian patients with Graves\u2019 ophthalmopathy","volume":"88","author":"Park","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"2026070710463327400_bvag069-B7","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/eye.2011.359","article-title":"Assessing Graves\u2019 ophthalmopathy-specific quality of life in Korean patients","volume":"26","author":"Choi","year":"2012","journal-title":"Eye (Lond)"},{"issue":"11","key":"2026070710463327400_bvag069-B8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jfma.2013.12.002","article-title":"Assessing quality of life in Taiwanese patients with Graves\u2019 ophthalmopathy","volume":"114","author":"Lin","year":"2015","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"2026070710463327400_bvag069-B9","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2026070710463327400_bvag069-B10","author":"Committee for the important clinical issue of the \u201cDevelopment of diagnostic criteria and treatment guidelines for malignant ocular protrusion of Graves\u2019 disease\u201d; The Japan Thyroid Association; The Japan Endocrine Society"},{"issue":"3","key":"2026070710463327400_bvag069-B11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jclinepi.2010.04.017","article-title":"Validation testing of a three-component model of short form-36 scores","volume":"64","author":"Suzukamo","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2026070710463327400_bvag069-B12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","article-title":"Interpretation and validity of changes in scores on the Graves\u2019 ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments","volume":"54","author":"Terwee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026070710463327400_bvag069-B13","first-page":"309","article-title":"A validation of the Hospital Anxiety and Depression Scale","volume":"38","author":"Hatta","year":"1998","journal-title":"Jpn J Psychosom Med"},{"issue":"3","key":"2026070710463327400_bvag069-B14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0149-7189(79)90094-6","article-title":"Assessment of client\/patient satisfaction: development of a general scale","volume":"2","author":"Larsen","year":"1979","journal-title":"Eval Program Plann"},{"issue":"17","key":"2026070710463327400_bvag069-B15","first-page":"283","article-title":"Quality of life and occupational disability in endocrine orbitopathy","volume":"106","author":"Ponto","year":"2009","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"2026070710463327400_bvag069-B16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2265.2007.03087.x","article-title":"The impact of thyroid eye disease upon patients\u2019 wellbeing: a qualitative analysis","volume":"68","author":"Estcourt","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026070710463327400_bvag069-B17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/OPX.0b013e3181ce5702","article-title":"Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases","volume":"87","author":"Kozaki","year":"2010","journal-title":"Optom Vis Sci"},{"issue":"3","key":"2026070710463327400_bvag069-B18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.beem.2011.10.004","article-title":"Ethnic differences in the clinical presentation of Graves\u2019 ophthalmopathy","volume":"26","author":"Chng","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026070710463327400_bvag069-B19","doi-asserted-by":"crossref","first-page":"1283374","DOI":"10.3389\/fendo.2023.1283374","article-title":"How patients experience thyroid eye disease","volume":"14","author":"Smith","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026070710463327400_bvag069-B20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/bjo-2022-322442","article-title":"Presentation of Graves\u2019 orbitopathy within European Group on Graves\u2019 Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)","volume":"108","author":"Schuh","year":"2024","journal-title":"Br J Ophthalmol"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvag069\/67602819\/bvag069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/7\/bvag069\/67602819\/bvag069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/7\/bvag069\/67602819\/bvag069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:05:06Z","timestamp":1783436706000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvag069\/8551312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,3]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvag069","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,27]]},"article-number":"bvag069"}}